Low rate increase of healthcare spending reported by CMS
WASHINGTON — The economic recession attributed to a mere 4% rise in healthcare spending, the slowest rate of growth in the 50-year history of the National Health Expenditure Accounts, according to the Centers for Medicare and Medicaid Services.
That number translates to $2.5 trillion, or about $8,086 per person.
CMS added that, despite the slowdown, healthcare spending growth continued to outpace overall economic growth, which declined 1.7% in 2009, as measured by nominal Gross Domestic Product.
As previously reported by Drug Store News, an analysis by the Kaiser Family Foundation’s Commission on Medicaid and the Uninsured found that the new health-reform law significantly would increase the number of people covered by the program.
No comments found
MMR vaccine, autism link was fabricated, medical journal says
NEW YORK — A study published in 1998 that led to a controversy over the measles-mumps-rubella vaccine was an “elaborate fraud,” according to a British medical journal.
Writing in the journal, BMJ, journalist Brian Deer reported that British physician Andrew Wakefield altered “numerous facts” about patients’ medical histories in a study he published in The Lancet that linked the MMR vaccine to a supposedly new syndrome of autism and bowel disease in children. The Lancet eventually retracted Wakefield’s study, after numerous subsequent studies found no evidence to corroborate it.
“Who perpetrated this fraud? There is no doubt that it was Wakefield,” BMJ’s editors wrote in an editorial. “Is it possible that he was wrong, but not dishonest? That he was so incompetent that he was unable to fairly describe the project, or to report even one of the 12 children’s cases accurately? No.”
The implications of Wakefield’s study and its refutation are enormous. The BMJ editors wrote that, thanks to the hysteria generated by the study, MMR vaccination rates in the United Kingdom dipped to 80% in 2003 and 2004, while the World Health Organization recommends rates of 95%. In 2008, health authorities declared a measles endemic in England and Wales. In Essen, Germany, 71 children at one school contracted mumps; 68 had not been vaccinated due to opposition by parents.
No comments found
Merck’s hepatitis C drug granted priority review by FDA
WHITEHOUSE STATION, N.J. — The Food and Drug Administration granted priority review to an approval application for a hepatitis C drug made by Merck, the drug maker said Thursday.
Merck said the FDA would seek to complete its review of the application for the drug boceprevir within six months. Authorities in the European Union have granted expedited review as well.
“We are pleased that the FDA and [European Medicines Agency] have accepted boceprevir for expedited review,” Merck Research Labs president Peter Kim said. “Our goal is to be able to bring forward a new treatment option for patients living with hepatitis C, and we are now closer to that goal.”
if and when approved what strand is it for i have geno type 3a